Kidney Cancer Patients Should Stop Smoking When Starting Sunitinib

Share this content:

Patients starting sunitinib (Sutent) treatment for metastatic renal cell carcinoma (mRCC) should be advised to quit smoking, as active smoking appears to negatively affect progression-free and overall survival in such patients, according to study findings published online ahead of print in The Oncologist.

The study, by Michael A. Carducci, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, and colleagues, focused on 278 patients (median age 63 years) with mRCC who underwent sunitinib therapy from 2004 to 2013. Among the participants, 67 were obese, 73 had diabetes, and 165 had pretreatment hypertension. Approximately half the patients were never-smokers, more than 20% were active smokers, and the remaining subjects had some history of smoking. Obesity, smoking, diabetes, and hypertension are all risk factors for the development of RCC.

After a median follow-up period of 55 months, a complete response was noted in 3% of patients, a partial response in 36%, stable disease in 39%, and progression in 22%. Median progression-free survival was nine months and median overall survival was 22 months. Ultimately, nearly 90% of patients had progressed and 73% had died.

Active smokers had significantly worse progression-free survival than did never-smokers (4 vs. 12 months) and significantly worse overall survival (11 vs. 25 months). The association between smoking and survival remained strong in additional analyses, one of which indicated that never-smokers and past smokers had a dramatically lower risk of showing progression on follow-up and had more than double the rate of progression-free and overall survival when compared with active smokers matched on age, gender, and a number of clinical characteristics.

References

  1. Keizman D, Gottfried M, Ish-Shalom M, et al. Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitini. Oncologist. 2013;doi:10.1634/theoncologist.2012-0335.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs